Every Form 4 that Edwards Lifesciences Corp (EW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EW filings page.
Edwards Lifesciences executive Donald E. Bobo Jr., CVP, Strategy/Corporate Development, exercised employee stock options for 11,340 shares and on the same day sold 11,340 shares of common stock at a weighted average price of $85.9286, under a pre-established Rule 10b5-1 trading plan. After these transactions, he directly owned 21,266.2532 shares, with additional indirect holdings of 38,900.5862 shares through a 401(k) and 121,756 shares held by a trust.
Edwards Lifesciences Corp executive Donald E. Bobo Jr., Corporate Vice President of Strategy and Corporate Development, reported an open-market sale of 24,000 shares of common stock on February 25, 2026 at a weighted average price of $83.8365 per share. After this sale, he directly owned 21,266.2532 shares. Indirect holdings were updated to 38,900.5862 shares through a 401(k) plan and 121,756 shares held by a trust, reflecting a correction of 13,396 shares that were previously reported as directly held. The sale price reflects multiple trades executed between $83.66 and $83.96.
Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, reported a tax-related share disposition. On February 22, 2026, he transferred 432 shares of common stock at a price of $79.78 per share to cover tax withholding. After this transaction, he directly owns about 33,933.9103 shares.
Edwards Lifesciences Corp senior vice president and corporate controller Andrew M. Dahl reported a Form 4 showing a tax-withholding disposition of 176 shares of common stock on February 22, 2026. The shares were disposed of at a reported price of $79.78 per share, and he now directly holds about 9,089.4805 shares.
Ullem Scott B. reported disposition transactions in a Form 4 filing for EW. The filing lists transactions totaling 199 shares at a weighted average price of $75.87 per share. Following the reported transactions, holdings were 39,699 shares.
Lippis Daniel J. reported multiple insider transaction types in a Form 4 filing for EW. The filing lists transactions totaling 13,276 shares at a weighted average price of $75.87 per share. Following the reported transactions, holdings were 34,366 shares.
Edwards Lifesciences CEO Bernard J. Zovighian reported several share transactions. On February 12, 2026, he exercised employee stock options covering 25,350 shares of common stock at an exercise price of $59.2567 per share. On the same day, he sold 2,532 shares at a weighted average price of $77.1287 and 19,898 shares at a weighted average price of $76.6133 in open-market transactions.
On February 13, 2026, he reported bona fide gifts of 2,920 shares of common stock at $0.0000 per share in a direct account and 2,920 shares reflected as indirectly held "By Trust." After these transactions, he directly held 80,976 shares, with an additional 11,516.5511 shares held indirectly by a trust and 3,655.5854 shares represented in his 401(k) plan.
Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, reported an option exercise and related share sale. On 01/09/2026, he exercised an Employee Stock Option for 1,019 shares of common stock at an exercise price of $59.2567 per share and acquired the underlying shares. On the same day, he sold 1,019 shares of common stock at a weighted average price of $85.7037 per share, in multiple trades executed between $85.45 and $85.95.
After these transactions, Lippis directly beneficially owned 22,001.9103 shares of Edwards Lifesciences common stock and 4,076 Employee Stock Options (right to acquire). The filing states that these transactions were carried out under a Rule 10b5-1 trading plan adopted by the reporting person on July 30, 2025.
Edwards Lifesciences reported insider transactions by its CVP, Strategy/Corp Development on 01/06/2026. The executive exercised an employee stock option for 11,340 shares of common stock at an exercise price of $59.2567 per share, then sold 2,632 shares at a weighted average price of $84.6206 and 8,708 shares at a weighted average price of $85.9793.
Following these transactions, the executive directly owned 31,870.2532 shares of common stock and also reported indirect ownership of 38,817.6991 shares through a 401(k) and 135,152 shares held by a trust. After the option exercise, 34,020 employee stock options remained beneficially owned. The filing notes that the transactions were carried out under a Rule 10b5-1 trading plan adopted on February 27, 2025.
Edwards Lifesciences (EW) reported insider activity by a senior executive. The company’s CVP, Strategy/Corp Development sold 5,486.1175 shares of common stock at $83.79 and 5,900 shares at $83.74 on 12/12/2025. On the same date, 7,100 shares were transferred as a gift at a stated price of $0.00. Following these transactions, the executive directly held 31,870.2532 shares of Edwards Lifesciences common stock, with additional indirect holdings of 38,817.6991 shares through a 401(k) plan and 135,152 shares held by a trust. The report notes that it reflects changes in beneficial ownership only and does not identify all securities of Edwards Lifesciences that the executive may beneficially own.
Edwards Lifesciences reported an insider transaction by a company officer serving as CVP, JAPAC. On 12/12/2025, the officer exercised an employee stock option for 1,019 shares of common stock at an exercise price of $59.2567 per share, then sold the same 1,019 shares in the open market at a weighted average price of $84.0287, with individual sale prices ranging from $83.58 to $84.46.
After these transactions, the officer directly held 22,001.9103 shares of Edwards Lifesciences common stock and 5,095 employee stock options. The filing states that the trades were carried out under a Rule 10b5‑1 trading plan adopted on July 30, 2025, which is a pre-arranged plan intended to allow insiders to sell shares over time according to preset instructions.
Edwards Lifesciences (EW) director reports a small stock sale. A company director filed to disclose the sale of 2,615 shares of Edwards Lifesciences common stock on 12/12/2025 at a price of $83.4109 per share, coded as an open market sale (transaction code "S").
After this transaction, the reporting person beneficially owns 30,948 shares of Edwards Lifesciences common stock in direct form. The filing is made by a single reporting person and expressly notes that it reflects only the change in beneficial ownership reported here and does not list all other securities of the company that the insider may own.
Edwards Lifesciences Corp
On 12/11/2025, the officer sold 2,000 shares of Edwards Lifesciences common stock at a price of $84.3751 per share. After this transaction, the officer beneficially owned 32,201 shares of the company’s common stock in direct ownership. The filing notes that it reflects changes in beneficial ownership only and does not list all securities of the issuer that may be beneficially owned by the reporting person.
Edwards Lifesciences Corp (EW) officer trades company stock through option exercise and sale. On 12/10/2025, the reporting person, a corporate vice president for strategy and corporate development, exercised an employee stock option for 11,340 shares of common stock at an exercise price of $59.2567 per share, then sold the same 11,340 shares at a weighted average price of $83.8255 per share in open-market transactions. These trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2025. After the transactions, the insider directly held 50,356.3707 shares, plus 38,817.6991 shares through a 401(k), 135,152 shares held by a trust, and 45,360 employee stock options.
Edwards Lifesciences CEO and director reported several equity transactions in company stock. On December 8, 2025, the insider exercised an employee stock option for 25,350 shares of common stock at an exercise price of $59.2567 per share, then sold 21,487 shares at a weighted average price of $85.2146. The option had been granted in 2019 under the company’s long-term stock incentive program.
On December 9, 2025, the insider transferred 3,863 shares from direct ownership and the same amount was recorded as held indirectly in a trust. On December 10, 2025, the trust sold 3,863 shares at $83.45 per share. After these transactions, the filing shows remaining direct and indirect holdings, including shares held through a trust and a 401(k). All reported trades were made under a Rule 10b5-1 trading plan adopted on February 28, 2025.
Edwards Lifesciences reported an insider stock transaction by its Chief Financial Officer, who serves as Corporate Vice President. On December 9, 2025, the executive exercised 7,700 employee stock options at an exercise price of $59.2567 per share, acquiring the same number of common shares. On the same date, the executive sold 7,700 shares of common stock at a weighted average price of $84.4691 per share. These trades were carried out under a Rule 10b5-1 trading plan adopted on July 29, 2025. After the reported transactions, the executive directly owned 39,898 shares of common stock and held 266,318 shares indirectly through a trust, along with 39,000 employee stock options that remained beneficially owned.
Edwards Lifesciences Corp executive reports small stock sale
An officer of Edwards Lifesciences Corp, serving as CVP, JAPAC, reported a routine sale of company stock. On 12/08/2025, the reporting person sold 583 shares of Edwards Lifesciences common stock at a price of $86.01 per share. After this transaction, the insider reported beneficial ownership of 17,562.8708 shares of common stock, held directly. The filing notes that it reflects changes in beneficial ownership only and does not identify any other securities of Edwards Lifesciences that may be beneficially owned by this person.
Edwards Lifesciences (EW) reported an insider equity grant. The company’s SVP, Corporate Controller, acquired 1,160 shares of common stock at $0.0000 on 11/13/2025.
The filing explains these restricted stock units were granted under the Long‑Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Following the transaction, the officer’s beneficial ownership was 9,183.074 shares, held directly. The filing also notes quarterly acquisitions under the Employee Stock Purchase Plan.
Edwards Lifesciences (EW) reported insider activity by its Chief Financial Officer. On 11/10/2025, the officer exercised employee stock options for 13,000 shares of common stock at an exercise price of $59.2567 per share and executed sales on the same date pursuant to a Rule 10b5-1 trading plan adopted on July 29, 2025.
The transactions included two sales: 2,974 shares at a weighted average price of $83.2999 (trades ranged from $83.270 to $83.415) and 10,026 shares at a weighted average price of $83.0201 (trades ranged from $82.270 to $83.260). Following these transactions, direct beneficial ownership stood at 39,898 shares, with an additional 266,318 shares held indirectly by trust. After the option exercise, 46,700 derivative securities (stock options) remained beneficially owned.
Edwards Lifesciences (EW) reported an insider Form 4 for an officer (CVP, JAPAC) on 11/10/2025. The reporting person exercised 1,020 employee stock options at $59.2567 and sold 1,020 common shares at a weighted average price of $82.5451, with trades ranging from $82.27 to $82.90. These transactions were made under a Rule 10b5-1 trading plan adopted on July 30, 2025. After the transactions, direct ownership was 22,001.9103 shares, and 6,114 derivative securities remained held directly.